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Abstract 
In colon cancer distinct genetic subtypes have been described, one of which involves 
overexpression of RAC1b, a variant generated by alternative splicing. Aberrant splicing 
is known to occur in cancer and can be caused by mutation in a gene or splicing factor 
but also represent a dynamic response to oncogene-induced cellular signaling and in 
this case it may be pharmacologically targeted. Here we explore how signaling 
pathways are involved in the deregulation of alternative RAC1b splicing in tumor cells. 
HT29 colorectal cells represent serrated colorectal tumors with BRAF gene mutation 
V600E in one allele and RAC1b overexpression. Cells were transfected with shRNA 
vectors directed against target candidate protein kinase transcripts and their effects 
on RAC1b levels analyzed 24h later by Western Blot and qRT-PCR. Treatment with 
kinase inhibitors or anti-inflammatory drugs was performed 24h prior to cell lysis. 
Because cell signaling involves protein kinases that can be targeted by inhibitory 
drugs, 20 candidate splicing-regulatory protein kinase genes were depleted by RNAi in 
HT29 cells. Two kinases, SRPK1 and GSK3β, were found required to sustain RAC1b 
levels and both were shown to act upon the phosphorylation of splicing factor SRSF1, 
which binds to and promotes the inclusion of the alternative exon in RAC1b. Reduced 
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SRSF1 phosphorylation decreased its nuclear translocation and concomitantly RAC1b 
splicing. This regulatory pathway is controlled by GSK3β and was found to be inhibited 
specifically by the anti-inflammatory drug ibuprofen.  
Together, our results demonstrate that oncogenic signal transduction pathways 
deregulate alternative splicing and this may be drug revertable. 
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